secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-05-12T13:20:15+00:00
Accession:  0001493152-26-022428
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025
---------------------------------------------------------------------------

- Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.
- Sales growth so far in 2026 exceeds internal projections, reflecting accelerating physician adoption.
- CyPath Lung uses flow cytometry + AI for noninvasive lung cancer detection; 92% sensitivity, 87% specificity in trial.
- Company advancing longitudinal clinical study, expanding use for lung cancer survivor monitoring, and R&D pipeline for asthma/COPD.
- CEO Maria Zannes highlights CyPath Lung's role in risk stratification and nodule management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226022428/0001493152-26-022428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226022428/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer